Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Thomas, Mittendorf"'
Autor:
Mareike Konstanski MSc, Kim Joline Schmidt MSc, Antje Rössel MSc PH, Dr. PH Andrej Rasch, Dr. rer. pol. Thomas Mittendorf
Publikováno v:
Monitor Versorgungsforschung, Vol 2023, Iss 02, Pp 61-65 (2023)
Ökonomische Langzeiteffekte von kostspieligen innovativen Therapien werden in Deutschland bei der Nutzenbewertung neuer Technologien vernachlässigt. Jedoch kann die Einbindung robuster Langzeitdaten ökonomische Anreize für Investitionen setzen un
Externí odkaz:
https://doaj.org/article/b17b3f2b21aa4e87b05c08bd6da076ea
Autor:
Kathrin Borchert, Christian Jacob, Natalie Wetzel, Martina Jänicke, Egbert Eggers, Annette Sauer, Norbert Marschner, Julia Altevers, Thomas Mittendorf, Wolfgang Greiner
Publikováno v:
Health Economics Review, Vol 10, Iss 1, Pp 1-14 (2020)
Abstract Background The EQ-5D-5L questionnaire is used in oncology to generate health-related quality of life (HRQoL) weights and corresponding health states. The purpose was to explore the relationship between demographic and clinical characteristic
Externí odkaz:
https://doaj.org/article/02d08fced2364f0c878ba47a074dfcbd
Publikováno v:
Dementia and Geriatric Cognitive Disorders Extra, Vol 2, Iss 1, Pp 146-159 (2012)
Two recent health technology assessment (HTA) reports published in Germany focused on non-pharmacological interventions for patients with dementia. One of the major results was the poor methodological quality of the studies in this field. This paper
Externí odkaz:
https://doaj.org/article/e5ad6473cd274c8394ad11a8f8f220bd
Autor:
Stefan Schreiber, Ulf Müller-Ladner, B Bokemeyer, Andreas Stallmach, Ulrich Mrowietz, T. Luger, J. Schröder, Thomas Mittendorf
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 139:2399-2404
Hintergrund: Die Behandlung chronisch entzundlicher Systemerkrankungen mit gezielt wirkenden biotechnologisch hergestellten Proteinen, den sogenannten Biologika, hat im letzten Jahrzehnt die Behandlungsmoglichkeiten in der Gastroenterologie, Rheumato
Autor:
Wolfram Karges, Hans-Joachim Schmoll, Christine Spitzweg, Thomas Mittendorf, Michael P. Lux, Christian Jacob, Matthias Schott, Klaus Mann, Michael C. Kreissl, Dagmar Führer, Markus Luster
Publikováno v:
Oncology Research and Treatment. 37:316-322
Background: Medullary thyroid cancer (MTC) is a rare tumor entity. The contents of best supportive care (BSC) have not been defined in advanced MTC. The objective of this work is to describe the epidemiology, the treatment patterns with respect to sy
Autor:
Ulrich von Hinüber, Ina Kötter, Thomas Mittendorf, Angela Zink, Guido Hoese, S. Bischoff, Dörte Huscher, Andrea Pfäfflin
Publikováno v:
Annals of the Rheumatic Diseases
Objective To estimate the changes in direct and indirect costs induced by patients with rheumatoid arthritis (RA) in German rheumatology, between 2002 and 2011. To examine the impact of functional status on various cost domains. To compare the direct
Autor:
Anne Prenzler, D. Hüppe, M. Düffelmeyer, M. Hoffstadt, S. Conrad, Bernd Bokemeyer, T. Klugmann, Thomas Mittendorf, Heiner Raspe, Carsten Schmidt, J. Hardt, J. Weismüller, P. Hartmann
Publikováno v:
Journal of Crohn's and Colitis. 7:355-368
Background The aim of this cross-sectional study was to establish an online inflammatory bowel disease (IBD) registry for a first picture of the situation of IBD outpatients' treatment in Germany. Methods Between March 2006 and July 2007 IBD outpatie
Autor:
Ivonne Thiessen, Eike Gunther Wüstenberg, Jean Pierre Allam, Kathrin Borchert, Ninette Troensegaard-Petersen, Niels Serup-Hansen, Thomas Mittendorf, Kathrin Damm, Andreas Horn, Janina Volk, Thomas Winkler
Publikováno v:
Health Economics Review 6 (2016), Nr. 1
Health Economics Review
Health Economics Review
BACKGROUND: Allergic Rhinitis (AR) is a common disorder in Europe with Allergic Asthma (AA) as a frequent comorbidity. Allergy immunotherapy (AIT) is the only causal therapy of AR and AA, and can be administered as subcutaneous injections at the phys
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 17(7)
Autor:
Petra Schnell-Inderst, Pamela Aidelsburger, Nikolai Mühlberger, Gaby Sroczynski, Alexander Krämer, Uwe Siebert, Thomas Mittendorf, Peter Hillemanns, Jutta Engel, Jürgen Wasem, Karl Ulrich Petry, K Lang
Publikováno v:
European Journal of Cancer. 47:1633-1646
Objectives: To systematically evaluate the long-term effectiveness and cost-effectiveness of HPV-based primary cervical cancer screening in the German health care context using a decision-analysis approach. Methods: A Markov-model for HPV-infection a